1. Home
  2. DSGX vs LEGN Comparison

DSGX vs LEGN Comparison

Compare DSGX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGX
  • LEGN
  • Stock Information
  • Founded
  • DSGX 1981
  • LEGN 2014
  • Country
  • DSGX Canada
  • LEGN United States
  • Employees
  • DSGX N/A
  • LEGN N/A
  • Industry
  • DSGX Computer Software: Prepackaged Software
  • LEGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • DSGX Technology
  • LEGN Health Care
  • Exchange
  • DSGX Nasdaq
  • LEGN Nasdaq
  • Market Cap
  • DSGX N/A
  • LEGN 9.1B
  • IPO Year
  • DSGX 1999
  • LEGN 2020
  • Fundamental
  • Price
  • DSGX $106.53
  • LEGN $45.57
  • Analyst Decision
  • DSGX Buy
  • LEGN Strong Buy
  • Analyst Count
  • DSGX 11
  • LEGN 13
  • Target Price
  • DSGX $106.00
  • LEGN $81.46
  • AVG Volume (30 Days)
  • DSGX 116.3K
  • LEGN 1.3M
  • Earning Date
  • DSGX 12-03-2024
  • LEGN 11-12-2024
  • Dividend Yield
  • DSGX N/A
  • LEGN N/A
  • EPS Growth
  • DSGX 13.00
  • LEGN N/A
  • EPS
  • DSGX 1.48
  • LEGN N/A
  • Revenue
  • DSGX $607,697,000.00
  • LEGN $455,991,000.00
  • Revenue This Year
  • DSGX $13.91
  • LEGN $108.95
  • Revenue Next Year
  • DSGX $10.76
  • LEGN $81.26
  • P/E Ratio
  • DSGX $72.41
  • LEGN N/A
  • Revenue Growth
  • DSGX 15.40
  • LEGN 176.93
  • 52 Week Low
  • DSGX $70.92
  • LEGN $38.60
  • 52 Week High
  • DSGX $108.02
  • LEGN $70.13
  • Technical
  • Relative Strength Index (RSI)
  • DSGX 57.33
  • LEGN 44.41
  • Support Level
  • DSGX $103.61
  • LEGN $44.56
  • Resistance Level
  • DSGX $107.38
  • LEGN $46.15
  • Average True Range (ATR)
  • DSGX 1.76
  • LEGN 2.05
  • MACD
  • DSGX -0.09
  • LEGN 0.19
  • Stochastic Oscillator
  • DSGX 65.53
  • LEGN 33.83

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Share on Social Networks: